Partner 3P Biopharmaceuticals received positive answer from AEMPS

Partner 3P Biopharmaceuticals received positive answer from Spanish AEMPS Agency of Medicines and Medical Devices (the Spanish Regulatory Agency), regarding the regulatory requirements for the manufacturing of the electroporation buffer, to be used in the Target AMD clinical trial I/II.

29. May 2015
Categories: Target AMD